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Abstract
The proceedings of the inaugural scientific meeting of the Society for Research on Nicotine and Tobacco
(SRNT) are summarized. The primary objective of the meeting was to foster the exchange of information on
the effects of nicotine and tobacco use, as well as factors which infiuence their use, drawing from biological,
behavioral and social sciences. Much of this research can be viewed as a tale of "two" drugs—nicotine as a
key to an important public health problem, and nicotine as a classical tool of physiological and pharmacolog-
ical research. A historical overview of research on "both" drugs is provided first. Public policy alternatives for
reducing the prevalence of tobacco use have been derived in part from basic and clinical research results and
are briefiy outlined. Evidence for genetic determinants on nicotine use and effects is presented using data from
twin studies and from molecular genetic research with humans and animals. Consistent with this research,
there is evidence of individual differences in pharmacokinetics and effects of nicotine, which could account for
differences in smoking behavior and nicotine dependence. Finally, recent developments in the therapeutic uses
of nicotine and novel nicotinic agonists with schizophrenia, Alzheimer's disease, Parkinson's disease,
Tourette's syndrome and ulcerative colitis are presented. Overall, the research presented at the meeting
demonstrated the vast diversity of areas of study involving nicotine and tobacco, as well as the rich
opportunities for cross-communication among researchers from different disciplines.
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Introduction
Research on nicotine and tobacco has grown in
volume as well as widened in scope, especially
over the past decade. With this growth has come
a splintering of the field, such that this research
is now presented at a myriad of meetings, rang-
ing from those focusing on molecular biology to
others emphasizing public health. Moreover, nic-
otine and tobacco too often comprise a very
small component of these meetings. Given this
divergence, it is increasingly uncommon for nic-
otine and tobacco researchers from these differ-
ent disciplines to come together and share their
findings.
The Society for Research on Nicotine and
Tobacco (SRNT) was organized in 1994 to pro-
vide a forum for the exchange of information
across the entire spectrum of research concern-
ing nicotine and tobacco use and effects. The
Society held its inaugural scientific meeting 24-
25 March, 1994 in San Diego CA. More than
220 registrants from nine countries attended the
forums, symposia. Master Lecture and paper
and poster sessions. Selected individual paper
and poster abstracts are presented elsewhere in
this issue. A summary of the other proceedings
follows.
Past, present, and future perspectives on
nicotine research
A new society can best gain its bearings by
placing itself in historical context. Such a context
was provided for the audience by SRNT Presi-
dent Ovide Pomerleau, Edward Domino, John
Hughes and former US Surgeon General Jesse
Steinfeld. In contrast to the current widespread
focus on the health impact of nicotine and to-
bacco use, nicotine was initially used as a tool in
pharmacology and physiology research earlier in
the century. For example, in 1905 John Langley
reported that low doses of nicotine stimulated
and high doses of nicotine "paralyzed" auto-
nomic ganglia. Moreover, as early as 1901 Lang-
ley's research on nicotine had already led him to
use the term "receptive substance" to character-
ize nicotine's effects at the neuromuscular junc-
tion. Hence, the birth of the term "receptor".
Similarly, Sir Henry Dale reported in 1914 that
nicotine could be used to differentiate choliner-
gic receptors into muscarinic and nicotinic types.
Because of such breakthroughs, nicotine was
known for a time as the "pharmacologic scalpel".
Although many of the basic questions remain,
such as what effects nicotine has in the brain,
most of the tools have changed, including use of
positron emission tomography (PET) scanning
of neural activity during nicotine exposure (Na-
gata et al., 1995). Further technological develop-
ments will only improve the precision with which
we understand nicotine's actions.
Knowledge of nicotine and tobacco use and
effects, of course, predates the 20th century.
Nicotine played important roles in indigenous
native American culture for more than 5000
years, including its use in religious and medicinal
rituals, as recorded in native art. Among the
most enthusiastic European proponents of to-
bacco use was Jean Nicot, French ambassador to
Portugal, in whose honor Catherine de Medici,
the 16th century French Queen, named the to-
bacco plant {Tabacum nicotiana). Misgivings
about the health effects of tobacco use were
sounded as early as the 17th and 18th centuries
but were overshadowed by the lucrative com-
mercial value and tax receipts resulting from the
tobacco trade (a portent of things to come). The
advent of the cigarette-rolling machine, the
safety match, improved tobacco blends and ad-
vertising all led to the tremendous growth of
tobacco smoking, and hence tobacco pro-
duction, around the turn of the 20th century.
Despite western societies' acknowledgement of
health risks associated with tobacco use over the
past 30 years, world-wide tobacco production
has continued to increase, with the result of
increasing prevalence of tobacco use in develop-
ing countries.
An overview of the current state of smoking
cessation treatment research was then presented.
Although the number of treatment studies focus-
ing on cessation of tobacco use has increased
almost exponentially since 1970 (Shiffrnan,
1993), there have been only a few legitimate
breakthroughs in the development of efficacious
interventions. Nicotine replacement therapy is
certainly one but has proved to be less than a
panacea (Hughes, 1993). Behavioral treatments
have also demonstrated efficacy, but they too fail
more often than they succeed with smokers try-
ing to quit. Future research into interventions for
smoking cessation will not bear fruit without
undertaking a fresh examination of nicotine and
tobacco reinforcement and the basic biological
and behavioral underpinnings of tobacco depen-
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dence. These treatments will also have to be
tailored to smokers who have other substance
use or psychiatric problems, such as alcohol de-
pendence or affective disorder, as well as to
under-served smokers for whom traditional
treatments are unavailable or inadequate.
A different approach society can take to re-
duce the prevalence of smoking is to support
governmental involvement in regulating tobacco.
Despite the logic of this approach, there are clear
practical obstacles limiting the likelihood of suc-
cess. Steinfeld recounted his own experiences in
fostering the rights of US non-smokers in 1971,
leading to his dismissal from US government
service soon after. He further outlined examples
of how political expediency can adversely
influence the actions of even the most sympath-
etic law-makers when it comes to attempts to
curb the health impact of smoking. Overall, this
session served to underscore the breadth of past
and current research into nicotine and tobacco
and to highlight how political, economic and
social issues surrounding tobacco often re-ap-
pear across the decades and even centuries.
Regulation of nicotine products in the US:
research issues
Taking a more optimistic stance in terms of
potential government involvement in control of
nicotine products, presenters in the subsequent
forum emphasized the relevance of findings from
basic and clinical research to the development of
strategies for limiting access to tobacco or to
nicotine exposure. Inquiries regarding the appro-
priate means to regulate nicotine and tobacco
products by the US Food and Drug Administra-
tion, the US Federal Trade Commission and the
US Congress in 1994 raised a broad range of
potential policy issues (Henningfield & Benow-
itz, 1995; Kozlowski & Henningfield, 1995), Im-
portantly, many of these issues can be evaluated
in the context of empirical research. Jack Hen-
ningfield, Lynn Kozlowski, Neal Benowitz, John
Slade, John Hughes and Charles Gruder de-
scribed a variety of approaches US and state
governments can take to regulate these products,
as well as the research supporting these ap-
proaches.
The driving force behind reappraisal of cur-
rent nicotine and tobacco regulatory approaches
is that the United States (along with the rest of
the world) is making unacceptable progress, or
even losing ground, in combating the impact of
tobacco use on public health, especially among
American youth and in developing countries. In
the United States, it appears that tobacco-related
deaths will remain at the level of 400 000 per
year or more for some time to come. Particularly
discouraging is that tobacco use among youth
appears to have increased somewhat over the
past decade. Worldwide, Peto and colleagues
(1992) estimate that half of all smokers vidll die
prematurely due to their smoking and that to-
bacco-related deaths will increase from 3 million
per year in the 1990s to 20 million per year by
the 2020s unless there are substantial decreases
in smoking behavior. Present trends suggest that
tobacco use has flattened after a period of de-
cline in the United States and is still on the rise
world-wide. It can thus be argued that present
regulatory approaches provide little in the way of
effective barriers to tobacco use. At the same
time, these approaches currently provide sub-
stantial barriers to the widespread use of effective
nicotine-replacement medication designed to as-
sist in the cessation of tobacco use.
Among the actions recommended was possible
revisions in the US Federal Trade Commission
(FTC) labeling of cigarettes with respect to their
delivery of nicotine, as well as tar and other
constituents (Henningfield, Kozlowski & Benow-
itz, 1994). Human laboratory and field research
has demonstrated for some time that stated nic-
otine yields of cigarette brands do not reflect
actual nicotine exposure by the smoker due to
the disparity between FTC machine smoking vs.
actual human smoking of cigarettes. An addi-
tional, longer-term strategy is to gradually reduce
the nicotine levels in cigarettes to the point that
they would not be considered pharmacologically
addicting (Benowitz & Henningfield, 1994),
Studies with humans and animals have begun to
identify the doses at which nicotine becomes
discriminable and reinforcing, providing a theor-
etical cut-off for cigarette yields. A third, more
extreme approach would be to severely restrict
access to nicotine in all forms, including tobacco,
by making it available by prescription only. This
position is supported by the view that tobacco
companies function in many respects as pharma-
ceutical companies, especially in terms of their
product development and manufacturing proce-
dures (e.g. Slade, 1995). Thus, their products
should undergo the same regulatory evaluation
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as other pharmaceutical products. Complement-
ing this approach is a strategy to make nicotine
replacement medications more readily available,
such as by allowing over-the-counter access. Fi-
nally, the importance of state, as opposed to US
federal, efforts to regulate and tax tobacco prod-
ucts was outlined, using California as an exam-
ple. Despite political obstacles to maintaining
the program (echoing comments by previous
speakers), proponents have shown that such a
program can lead to reduced prevalence of
smoking, especially among youth, and that tax
revenues can be used to enhance the support of
tobacco-related research.
Genetic influences on use and efifects of nic-
otine and tobacco
Tobacco products are available virtually
throughout the world, and nearly all teens exper-
iment WiXh tobacco use. Yet, in most societies,
fewer than half of adults are regular users of
tobacco. Thus, the issue of why some people are
at heightened risk for the adoption and/or
maintenance of smoking remains of enormous
concern to public health officials as well as to
those responsible for allocation of increasingly
scarce health care resources. Evidence from sev-
eral lines of research suggests that the use and
effects of nicotine or tobacco smoking is
influenced in part by genetic factors. Gary Swan,
Andrew Heath, Allan Collins, Ernest Noble, and
Gerald McCleam presented recent studies in
support of this notion.
More than 20 studies have examined tobacco
use in monozygotic and dizygotic twins, demon-
strating that both smoking initiation and persist-
ence are regulated by genetic factors. One of the
more recent studies used information on smok-
ing history for 4775 pairs of US twins surveyed
in 1967-69 and then again in 1983-85 (Carmelli
et al., 1992). The large sample size permitted
classification by smoking status, smoking inten-
sity (number of cigarettes per day), and smoking
cessation at follow-up. Genetic influence (i.e.
greater concordance in monozygotic vs. dizygotic
twins) was most strongly seen at the tails of the
distribution of smoking intensity (low and high
number of cigarettes per day) and was also ob-
served for cessation at follow-up. Other twin
studies from Finland, Sweden, Australia, Eng-
land, and the United States provide heritability
estimates (i.e. proportion of total variance in risk
attributable to genetic effects) in the range 28-
83% for smoking initiation and 53-71% for per-
sistence, with the genetic influences on each
being independent of the other (Heath et al.,
1995). Notably, findings are as great in women
as in men and appear to be comparable to those
from studies on alcoholism. At least some of the
genetic contributions to risk of becoming a
smoker may be mediated through differences in
personality (e.g. novelty seeking, social confor-
mity) and educational attainment. On the other
hand, these variables are only weakly predictive
of smoking persistence, leaving unanswered the
question of how genetic influences on persist-
ence arise. In addition, the extent to which gen-
etic differences in initial sensitivity or in rate of
acquisition of tolerance to nicotine may
influence risk of nicotine dependence, as well as
probability of becoming a long-term persistent
smoker, remains a critical issue. Further twin
research should: incorporate refined indices of
nicotine dependence (such as laboratory mea-
sures of nicotine sensitivity and metabolism),
examine potential moderating influences of gen-
der, and investigate genetic influences on the
joint use of tobacco, alcohol and other sub-
stances.
Animal research has addressed many of these
issues with impressive precision. Studies by
Collins and others have attempted to identify
components of the dependence process that are
regulated by genetic factors (e.g. Marks et al.,
1991). Using inbred mouse strains, selectively
bred mouse lines and recombinant inbred
strains, they have shown that genetic factors
regulate sensitivity to a first dose of nicotine, the
development of acute and chronic tolerance to
nicotine, and preference for nicotine-containing
solutions in a choice test. Initial sensitivity, re-
lated to number of brain nicotinic receptors, also
seems to be a predictor of tolerance and self-ad-
ministration. Quantitative trait loci analyses have
identified other candidate genes that are cur-
rently being investigated.
Complementing this animal work are very re-
cent molecular genetic studies in humans sug-
gesting the importance of certain gene variants of
the dopaminergic system in smokers (Noble, et
al., 1994). For example, Noble has very recently
found a higher prevalence of gene variants of the
D2 dopamine receptor (DRD2) among active
and ex-smokers compared with never-smokers in
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a sample of 169 Caucasian women (100 never-
smokers, 69 current or ex-smokers) and 164
Caucasian men (96 never-smokers, 68 current or
ex-smokers). Analysis showed that male smokers
carrying the Taq I DRD2 Al allele (Al/Al or
A1/A2 genotype), as opposed to those carrying
the A2 allele (A2/A2 genotype only), began to
smoke regularly at a significantly earlier age
(15.9 vs. 18.3 years). However, there was no
difference due to genotype for female smokers.
To attempt to better understand this gender
difference, the influence of body mass index
(BMI) was considered. Of the females, 92 were
non-obese and 77 were obese, while of the males
85 were non-obese and 79 were obese. No
significant differences in BMI were found among
the Al and A2 allele non-smoker females and
males. However, significant differences were
found among the four groups of smokers.
Specifically, BMI was lower in Al allele com-
pared to A2 allele female smokers, while this
difference was reversed for male smokers. Simi-
lar results were observed in analyses of Intron
6/Exon 7 alleles. Thus, genetic analyses of smok-
ing should consider the moderating influences of
other heritable conditions, such as obesity.
In evaluating the current state of this genetic
research McCleam noted that, until recently,
there were only two general approaches to study-
ing pharmacogenetics: the single gene and quan-
titative genetic approaches. The single gene
approach is attractive because success in identi-
fying a single locus frequently points to a poss-
ible mechanism. However, in many important
phenotypes there appears to be no single gene
that accounts for variability in the population.
An alternative "differential" model (McCleam,
1993), based on quantitative genetic theory, ac-
counts for multiple genetic and environmental
influences impinging on a common "causal
field", leading to the phenotype under examin-
ation. Principal features displayed by the model
are the widespread ramifications of allelic differ-
ences at a single locus (pleiotropy), the influence
of multiple loci on complex phenotypes
(polygeny), and the genetic and environmental
origins of correlations among phenotypes. Since
every human is unique in terms of genetics and
environmental experience, individual variability
is a fundamental feature of any biological system,
not just a reflection of "error". Findings from
genetic studies can perhaps be more clearly
understood in the context of this "differential"
model. Further advances in behavioral and mol-
ecular genetic research will likely provide a
clearer understanding of the biobehavioral bases
of nicotine dependence and, consequently, aid in
the development of improved methods for as-
sessment and treatment of dependence.
Individual differences in nicotine dispo-
sition and effects in humans
As suggested in the genetic research previously
discussed, individual differences in the initiation
and persistence of tobacco use, as well as in the
development of adverse health effects of smok-
ing, are well recognized. The bases for these
individual differences are as yet unknown but
could involve differences in metabolism and/or
pharmacodynamics of nicotine. Neal Benowitz
presented a Master Lecture describing recent
research findings on individual differences in nic-
otine disposition and effects.
The pattern of nicotine metabolism has been
nearly completely characterized, with 90% of a
dose of nicotine recoverable in the urine. How-
ever, there is considerable individual variability
in patterns of metabolism, which could contrib-
ute to individual variability in susceptibility to
nicotine addiction in two ways. First, the rate of
nicotine metabolism could influence how much
people smoke. For example, a person who me-
tabolizes nicotine quickly may need to smoke
more to achieve a particular level of nicotine
than does a person who metabolizes nicotine
more slowly. Secondly, the pattern of nicotine
metabolites (including cotinine, nicotine
iminium ion, beta-nicotyrine, nomicotine) that is
generated could affect smoking behavior since
some of these metabolites may be pharmacologi-
cally active.
Among smokers, there are four-fold differ-
ences in nicotine clearance. Using deuterium-
labeled nicotine and cotinine, the disposition
kinetics of nicotine have been studied in a variety
of patient populations. A comparison of smokers
and non-smokers indicated that nicotine metab-
olism is slightly faster in non-smokers (Benowitz
& Jacob, 1993). Thus, metabolic tolerance does
not appear to be a factor in the natural history of
tobacco addiction.
Conversion of nicotine to its major metabolite,
cotinine, has been the subject of recent research
into individual differences. In a group of 20
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smokers it was determined that, on average, 72%
(range 55-92%) of nicotine is converted to co-
tinine (Benowitz & Jacob, 1994). Using data
from several sources a factor was derived that
relates cotinine concentration to daily nicotine
intake. This factor averages 0.08, such that a
typical plasma cotinine level of 300 ng/ml corre-
sponds to a daily intake of 24 mg nicotine. Yet,
one individual has been found to convert only
9% of nicotine to cotinine (Benowitz, Sachs &
Jacob, 1995). This individual also had abnor-
mally slow elimination of nicotine (three-fold
prolongation of nicotine half-life). The biological
consequences of tbis deficient C-oxidation of
nicotine is unclear but could be considerable.
Ethnic differences in nicotine metabolism have
been hypothesized to contribute to differences in
health effects and/or susceptibility to nicotine
addiction in blacks vs. whites. Notably, cotinine
levels per cigarette smoked are significantly
higher in blacks, and blacks have higher rates of
lung cancer at any given level of smoking, com-
pared with whites. To examine whether metab-
olism of nicotine or cotinine could be involved,
labeled nicotine and cotinine infusions were ad-
ministered to 40 black and 39 white smokers
matched for age, gender and self-reported
cigarette consumption (Benowitz et al., 1995).
Nicotine clearance and percentage conversion to
cotinine were similar between blacks and whites,
but cotinine clearance was significantly slower
(and cotinine half-life longer) in blacks. Intake of
nicotine per cigarette was also higher in blacks.
These data clarify higher cotinine levels per
cigarette smoked in blacks, although tbeir rela-
tionsbip to differential rates of nicotine addiction
and health risks are still unclear. Collaboration
between clinical pharmacologists and geneticists
may clarify many of the mechanisms accounting
for these individual differences in nicotine
metabolism.
Aside from individual differences in nicotine
metabolism, variability in magnitude of effects of
nicotine may also impact on nicotine addiction
and health effects. Increasingly clear is tbe fact
that effects of nicotine depend on tbe rate of
dosing (Porcbet et al., 1987) Tbus, rapid dosing
results in greater effects because of tbe resulting
higher arterial concentrations of nicotine, com-
pared with slow dosing. Pbarmacodynamic stud-
ies have also focused on tbe relationship between
plasma nicotine concentrations and effects over
time, with particular emphasis on tbe develop-
ment of tolerance. Tolerance, which can be
defined as reduced magnitude of drug effect with
repeated exposure, is considered a key to tbe
onset of pbysical dependence. Pbarmacokinetic-
pbarmacodynamic modeling has been used to
cbaracterize acute tolerance to specific nicotine
effects (Porcbet, Benowitz & Sbeiner, 1988). For
example, tbis method bas determined tbat acute
tolerance to tbe beart rate acceleration effects of
nicotine bas a balf-life of 35 minutes. Further-
more, tbis model indicates tbat at a steady state
plasma nicotine concentration of 25 ng/ml, typi-
cal of levels observed in smokers, tbe beart rate
acceleration effect of nicotine is only 20% of tbat
observed in tbe absence of tolerance. These re-
sults mirror beart rate effects of smoking over tbe
course of a day, with substantial increases due to
tbe first few cigarettes of tbe day, followed by
plateauing in tbe face of rising nicotine levels.
Similar pbarmacodynamic parameters have been
observed for blood pressure effects and tbe
epinepbrine releasing effects of nicotine. In con-
trast, tolerance to nicotine's effects on energy
expenditure develops more rapidly, suggesting a
different mecbanism of action for tolerance to
tbis effect vs. cardiovascular effects. Use of these
methods to examine individual differences in
tolerance development may provide a mecban-
ism or marker of differential susceptibility to
nicotine addiction.
Therapeutic potential of nicotine and nico-
tinic agonists
As previously noted, tbe SRNT meeting opened
with a recounting of some of tbe history of
nicotine researcb, and it was pointed out tbat
nicotine bas long been a useful tool for re-
searcbers interested in probing tbe nervous sys-
tem. Perhaps nowhere is tbis vein of researcb
more alive and well tban in tbe study of possible
tberapeutic uses of nicotine. Altbougb tbe bealtb
risks associated with its intake via tobacco prod-
ucts bas tended to tamisb society's view of nic-
otine, it is important to recognize tbat nicotine
may have tberapeutic potential witb a number of
disease states. Paul Newbouse, Robert Freed-
man, Paul Sanberg, Marc Silverstein and Steven
Americ described developments in tbe use of
nicotine, nicotinic antagonists and novel nico-
tinic agonists in the investigation and treatment
of neuropsycbiatric and gastrointestinal condi-
tions.
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Tobacco smoking is extremely prevalent
among those with the psychiatric disorder of
schizophrenia. Part of the reason they smoke so
heavily may be to improve ability to screen out
irrelevant sensory information. Schizophrenics
show impairment in this ability, whieh may be
related to an impairment of inhibitory mecha-
nisms that act to decrease attention to repeated
stimuli (i.e. sensory gating). One of the neuronal
mechanisms responsible for such gating involves
the activation of nicotinie receptors in the
hippocampus. These receptors have been found
to be diminished in schizophrenics at autopsy.
Investigations in living patients have shoviTi that
schizophrenics and 50% of their first-degree rela-
tives show deficient sensory gating to repeated
auditory stimuli (P50). Nicotine transiently re-
stores normal suppression (gating) of P50 re-
sponses, with effects lasting 15-30 min.
Pretreatment of subjects with the ganglionic-type
(C6) nicotinic antagonist mecamylamine (10
mg) did not block the restoration of gating,
suggesting that this effect of nieotine may be
mediated through bungarotoxin-type nieotinic
receptors. Studies of the hippocampal nicotinie
reeeptor that may be responsible for the gating
effeets show that the alpha-bungarotoxin sensi-
tive receptor consists solely of alpha-7 subunits.
These reeeptors oceur on intemeurons in the
dentate hilus and CA3 regions of the hippoeam-
pus. Recently, the gene encoding the alpha-7
nieotine reeeptor unit has been localized to
15ql4. Preliminary studies of families with
schizophrenia and the P50 gating abnormality
showed linkage to this ehromosomal location.
Therefore, medications to improve sensory gat-
ing in these patients may be an attractive thera-
peutic target (Freedman et al., 1994).
Nicotine may also be efficacious in augment-
ing neuroleptie therapy in patients with
Tourette's syndrome (TS). TS usually begins in
childhood and is eharaeterized by multiple motor
and voeal tics. Treatment of choice is dopamine
antagonists such as haloperidol. However, some
patients do not fully respond to such agents and
full suppression is not possible in others due to
dose-limiting side-effeets. In animals, nieotine
markedly potentiates the cataleptic effects of
neuroleptics while not producing these effeets
when administered alone (Emerich et al., 1991).
This action appears to be mediated through in-
teractions at striatal D2 reeeptors as nieotine
does not potentiate eataleptie effeets of selective
Dl antagonists. Drawing from this research,
Sanberg provided nicotine polacrilex (gum) to
TS patients (adults and children) who had only
partially responded to haloperidol, finding
significant relief of symptoms as soon as 20 min
after nieotine administration. Improvement was
observed in both frequeney and severity of motor
and vocal tics as well as in improved eoncen-
tration and attention. Difficulties in administra-
tion and compliance with the gum have led to
similar research with transdermal nicotine, whieh
has resulted in improvements similar to that
firom gum, especially in non-smokers. Unexpect-
edly, some patients showed prolonged sup-
pression of symptoms after a single exposure to
nieotine, with amelioration lasting up to several
weeks (Silver & Sanberg, 1993). While the
meehanism(s) behind this augmentative effeet of
nieotine remains unclear, the eaudate nucleus
appears critical, as direct injections into the eau-
date ean replieate the effeet of systemic adminis-
tration in rats and lesioning the caudate
obliterates the response.
Interest in the role of nieotinic systems in the
cognitive disorder of Alzheimer's disease (AD)
increased after the development of technology to
map central nervous system (CNS) nieotinie re-
ceptors. Subsequently, AD patients have been
shown to have a marked reduction in brain nieo-
tinie receptor density compared to age-matched
controls. Newhouse examined the potential ef-
feets of nieotine reeeptor loss on cognitive func-
tion by administering the nicotine antagonist
mecamylamine to young and old normals, AD
and Parkinson's disease (PD) patients. Meeamy-
lamine produced dose-related impairment in
acquisition of new verbal or non-verbal infor-
mation, with a significant shift to the left in dose
sensitivity with age and disease state (Newhouse
et al., 1994). PD patients did not show the
sensitivity to nieotinie blockade that AD patients
did, despite a prior finding that PD patients also
show loss of nieotinie receptors. Dopamine-ago-
nist treatment of sueh patients may have pre-
vented effects of mecamylamine. Studies with
intravenous nicotine in AD patients have shown
that nicotine ean improve cognitive function in
many of the same cognitive domains, with a
dose-related deeline in verbal learning errors and
increase in long-term recall (Newhouse et al,
1993). These results suggest that nicotinic
modulation may alleviate cognitive impairments
in various dementing disorders whieh show loss
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of nicotinic receptors. Nicotine is unlikely to be
an ideal candidate for this task due to its low
therapeutic index but other, more selective, ago-
nists may be more useful, as discussed below.
Illustrative of the diversity of sites of nicotine's
actions in the body is preliminary evidence of its
role in inflammatory bowel disease. Silverstein
reported that in the 1980s there were case re-
ports of patients with ulcerative colitis (UC) in
which symptoms began immediately after smok-
ing cessation or improved after resuming smok-
ing or chewing nicotine gum. An early
case-control study demonstrated that current
smokers had reduced risk (odds ratio (OR) of
0.31) and former smokers had slightly increased
risk (OR= 1.16) of being diagnosed with UC,
compared with the general population. Silver-
stein and colleagues (1994) have also performed
a case-control study, controlling for factors
known to be associated with UC, such as race,
religion and socio-economic status. Results
showed that current smokers had an adjusted
OR of 0.22 and former smokers had an adjusted
OR of 1.6 for UC. Risk of onset for UC is
substantially increased shortly after quitting
smoking (OR of 7.5 in first 2 years after quitting
but 0.44 6 years after quitting). Initial clinical
trials wixh nicotine gum in UC have shown im-
provement in about half of patients when it is
added to their normal therapeutic regimen. A
recent double-blind study of 6-week treatment
with nicotine patches has also shown significant
improvements in global clinical and histological
appearance, less symptoms and more complete
remissions. In contrast with this relationship be-
tween smoking and UC, patients with another
major inflammatory bowel disease, Crohn's dis-
ease (CD), are more likely to be smoking at the
onset of symptoms (OR =3.7) and to show
therapeutic improvement after smoking cessation
(Silverstein et al., 1989). Thus, further study of
nicotine's gastrointestinal mechanisms of action
is clearly needed.
The research reviewed clearly indicates thera-
peutic potential for nicotine. However, develop-
ment of novel nicotinic agonists may provide for
greater efficacy and reduced side-effects, as pre-
sented by Americ. With increased understanding
of the molecular biology of the nicotinic acetyl-
choline receptor (NAR), new molecules are be-
ing developed which have enhanced selectivity
for nicotinic receptor subtypes or which may be
allosteric modulators of nicotinic receptor func-
tion. One of these is ABT-418, a potent and
selective NAR agonist which appears to be rela-
tively selective for alpha-4 beta-2 NAR subtype
(Americ et al., 1994). It has little activity at the
bungarotoxin-labeled NAR site (alpha-7) or at
the neuromuscular junction. Mecamylamine
blocks effects of ABT-418 on activating NAR
channel currents in PC 12 cells, suggesting that
ABT-418 is a ganglionic-type nicotinic agonist.
Animal studies show that ABT-418 has positive
effects on inhibitory avoidance at lower doses
than nicotine (which is blocked by mecamy-
lamine), restores normal performance in septal-
lesioned rats, enhances primate performance on
delayed matching-to-sample tasks, and produces
anxiolysis similar to non-benzodiazepine anxi-
olytics (Garvey et al, 1994). However, unlike
nicotine, ABT-418 does not produce changes in
free-running EEG. Other nicotinic agonists un-
der development include GTS-21, an anabaseine
derivative which may have activity at alpha-7
NARs and may be neuroprotective. Another ago-
nist, S-1663, appears to be selective for alpha-3
beta-4/2 NARs and may selectively enhance do-
pamine release and reduce neuroleptic-induced
catalepsy. Aside from their potential therapeutic
efficacy with Alzheimer's and Parkinson's dis-
eases, novel NAR may have potential in treating
benign familial neonatal convulsions and as anal-
gesics.
Understanding the regulatory role of nicotine
receptors and their underlying molecular and
cellular biology is increasing rapidly. This re-
search may lead to a new era in the development
of selective nicotinic agents for a variety of dis-
ease states.
Conclusion
The inaugural scientific meeting of the Society
for Research on Nicotine and Tobacco was orga-
nized to foster the exchange of information on
the effects of nicotine and tobacco use, as well as
factors which influence their use, drawing from
biological, behavioral and social sciences. Much
of this research can be viewed as a tale of "two"
drugs—nicotine as a key to an important public
health problem, and nicotine as a classic tool of
physiological and pharmacological research.
Overall, the research and policy issues presented
at the meeting demonstrated the vast diversity of
areas of study involving nicotine and tobacco, as
well as the rich opportunities for cross-com-
SRNT Conference Summary 137
munication among researchers from different
disciplines.
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